Cases & Deals

  • Home
  • Practices
  • Takeda expands patent portfolio relating to anticancer drugs and clinical stage anticancer drug candidates

Share

Takeda expands patent portfolio relating to anticancer drugs and clinical stage anticancer drug candidates

November 2017

Client(s) Takeda Pharmaceuticals U.S.A., Inc.

Jones Day represents Takeda Pharmaceuticals U.S.A., Inc. in worldwide patent prosecution and portfolio development for approved and clinical stage anticancer drugs and drug candidates, including ALUNBRIGTM (brigatinib), which is indicated for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.